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Summary 
Peritonitis exudate reveals strong proteolytic activity which is paralleled by deficient opsonic capacity 
and high concentrations of lysosomal proteinases (elastase and cathepsin B). Lysosomal serine and 
cysteine proteinases (elastase, cathepsins B, L) were shown to degrade Immunoglobulin G(IgG) and 
seem to be at least partially responsible for the observed proteolytic inactivation of IgG in Peritonitis 
e x u d a t e s . I n t r a a b d o m i n a l s e r u m application seems to restore o p s o n i c activity by Substitution of Opsonins 
and Proteinase inhibitors. 
Introduction 
Diffuse Peritonitis is initially a localized intraabdominal inflammation. The breakdown of 
local defense mechanisms results in systemic complications like bacteriemia and toxinemia 
with subsequent sepsis and multi-organ failure. Lethality of Peritonitis remains to be as high 
as 24% — 54%. After surgical t reatment of the source of Peritonitis, the patient's fate depends 
mainly on the efficiency of the defense System. Peritonitis exudate is characterized by a 
large spectrum and number of viable bacteria despite the presence of intact phagocytes. In 
previous work we have been able to demonstrate a pronounced impairment of opsonisation 
in Peritonitis exudate due to proteolytic breakdown of the Opsonins Immunoglobulin G(IgG) 
and complement factor C3 [1], We have now further analysed this proteolytic activity and 
investigated a therapeutic approach by intraabdominal serum application. 
Material and methods 
Biochemical studies 
Human Peritonitis exudate was taken dur ing Operations. All factors were measured in cell-free super-
natant. Opsonic activity was determined by a special chemiluminescence (CL) assay [1]. Granulocytic 
elastase (in complex with approteinase inhibitor) was measured by ELISA [2], cathepsin B activity 
with a fluorogenic peptide Substrate using the specific cysteine Prote inase inhibitor E-64 [3]. 
Proteolytic activity of exudates was estimated by the fluorescence of non-precipitable fragments released 
from resorufin-labelled casein (Boehringer, Mannheim). 
Human IgG (Sigma) was incubated with 2% (w/w) of papain (Sigma), human cathepsin B, H, L 
(Medor, D-8036 Herrsching) at pH 5.5 and with human leucocyte elastase (Medor) at pH 7.4 for 18 h 
at 30 °C. Fluorescein isothiocyanate (FITC)-labelled IgG was added to cell-free exudate (pH about 
7.0) and incubated under the same conditions. IgG or FITC-labelled IgG and their proteolytic fragments 
400 A. B I L L I N G et al. 
were separated by fast gel chromatography o n a Superose 12 FPLC column (Pharmacia) and detected 
by photometry at 280 nm or continuous fluorometry (Excitation: 486 nm, emission: 513 nm) using 
H PLC detectors. Prior to use, FITC-labelled IgG (Sigma) was purified by FPLC on the same column. 
Therapeutic serum application 
By the end of the Peritonit is Operation and after thorough lavage of the whole abdomen with 10 I of 
Ringer Iactate Solut ion, 300 ml of blood bank serum were applied into the abdomen. Controls were 
without serum application. In both g roups , abdominal drainage fluid was collected and pooled from 
0 — 1 h, 1 — 2 h and 2 — 8 h after Operation. 
Results and discussion 
Proteolytic activity of exudates 
Proteolytic activity of exudates was compared with their opsonic capacity as well as with 
their content of complexed elastase and their cathepsin B activity (Fig. 1). Exudates with 
high opsonic deficit (low opsonic capacity) showed high concentrations of lysosomal 
proteinases and high caseinolytic activity. 
Limited proteolysis of human IgG by isolatcd lysosomal proteinases was followed by gel 
chromatography (Fig. 2). Catalytic amounts of leucocyte elastase as well as cathepsins B 
and L cleaved human IgG into (Fab)2 , Fe and/or Fab fragments. The same type of cleavage 
was observed with FITC-labelled IgG incubated with cell-free exudate. IgG proteolysis was 
significantly reduced in the presence of E-64, a specific inhibitor of cysteine proteinases. 
Clinical therapeutic study 
Normal serum contains high amounts of intact Opsonins as well as protein inhibitors of 
serine and cysteine proteinases. Preliminary results inclicate an increased opsonic activity 
of peritoneal exudate for at least eight hours after intraabdominal serum application as 
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Fig. 2. Limited proteolysis of human immunoglobulin G (IgG) by isolated lysosomal proteinases and 
by Peritonitis exudate. 
IgG and IgG fragments were separated by fast gel chromatography on a Superose 12 FPLC column. 
Spikes along the elution profiles indicate fractions of 1.3 min (flow rate 0.2 ml/min). A, intact IgG; 
B, (Fab)2 fragments; C, Fe and/or Fab fragments; D, low-M r buffer peak present in all samples 
Conclusions 
Peritonitis exudate reveals strong proteolytic activity which is paralleled by high levels of 
lysosomal serine and cysteine proteinases. Proteolytic breakdown of defensive proteins by 
phagocytic (and bacterial?) proteinases may be a pathobiochemical key factor in Peritonitis. 
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Fig. 3. Effect of intraabdominal serum 
application on opsonic capacity of Peri-
tonitis exudate ( ) as compared 
to controls without serum application 
( )• 
— • —, mean of serum group (/? = 5» 
+ SEM; — A —, mean of control group 
(n = 6) ± SEM. Samples: preL, imme-
diately after laparotomy; postL, after 
lavage with 101 of Ringer lactate Solu-
tion; dl h — d8 h, pooled fractions of 
postoperative drainage fluid after 1. 2 
and 8 h 
preL postL d1h d2h d8h 
Local serum application seems to restore opsonic activity during the crucial first hours 
after Peritonitis Operation. These preliminary findings will be further investigated in a 
randomized clinical study. 
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